Hematopoietic stem cells contribute to mammalian brain tissue regeneration by transdifferentiation processes. We found decreased counts of circulating CD34 þ cells in early Alzheimer's dementia (AD; P = 0.01), which significantly correlated with age (r = À0.661; P = 0.001), cerebrospinal fluid b-amyloid (Ab)1-42 (r = À0.467; P = 0.025) and most pronounced the Ab42/40 ratio (r = À0.688; P = 0.005). Our data suggest a deficient regenerative hematopoietic support for the central nervous system in early AD.
Introduction
Alzheimer's disease (AD) is characterized by the deposition of b-amyloid (Ab) peptides into neuritic plaques, the formation of neurofibrillary tangles, neuroinflammation and the degeneration of synapses and neurons in brain regions critical for learning and memory. 1 In the mammalian brain, neurogenesis originating from neuronal stem cells persists in adulthood, but it decreases with age. 2 Neurogenesis responds to environmental demands such as brain injury or mental activity. 3, 4 Neogenesis of neuronal and glial cells also occurs by transdifferentiation of hematopoietic stem cells (HSC) from the peripheral blood, suggesting that a regenerative interface exists between the nervous and hematopoietic organ systems. [5] [6] [7] This view is strengthened by findings showing that stress related to ischemic stroke triggers the mobilization of HSC into peripheral blood. 8 Recently, it was shown that intracerebral HSC implantation induced neuroplasticity and improved neurological function in rats after chronic cerebral ischemia. 9 Therefore, central nervous system regeneration by transdifferentiation of HSC might be relevant for diagnosis and therapy of neurodegenerative diseases. This study was undertaken to evaluate the frequency of HSC in the blood of patients with early AD.
Materials and methods
The study protocol was approved by the Ethics Committee of the University of Erlangen-Nuremberg and all participants provided written informed consent. The early AD group fulfilled the NINCDS-ADRDA criteria for probable AD and the diagnosis was supported by cerebrospinal fluid (CSF)-based neurochemical dementia diagnostics using commercially available enzyme-linked immunosorbent assay kits to assess Ab1-40, Ab1-42, tau and phospho-tau proteins (The Genetics Company, Zurich, Switzerland; Innogenetics, Ghent, Belgium). 10, 11 Spouses or caregivers served as non-demented age, sex and environmentally matched controls.
Monoclonal antibodies (mAbs) directed against CD45R0-fluorescein isothiocyanate (FITC), CD34-phycoerythrin (PE) and isotype controls were purchased from Becton Dickinson (Heidelberg, Germany). One hundred microlitres of ethylenediaminetetraacetic acid (EDTA)-anticoagulated whole blood were incubated with the respective mAb at a concentration determined in pretitrating for 30 min at 41C. Erythrocytes were removed with the Multi-Q-Prep/ImmunoPrep systems (Beckman Coulter, Fullerton, CA, USA). Cells were washed, fixed with phosphate-buffered saline/1% paraformaldehyde (pH 7.4, 41C) and analyzed by flow cytofluorometry (EPICSXL, Beckmann Coulter, USA). HSCs were identified as CD34 þ and by low levels of CD45R0 expression (CD45R0 low ) to exclude irrelevant populations of mature blood cells. 12 Statistical calculations were performed using the SPSS 12 software (SPSS Inc., Chicago, IL, USA). All statistical tests were two-sided and the significance level was set at a = 0.05. Statistical significance was assessed using t-tests for unpaired samples. The normal distribution of the data was confirmed with the Kolmogorov-Smirnov test with Lilliefors correction, variance homogeneity was assessed according to Levene and correlation coefficients were determined using the method of Pearson.
Results
We performed a pilot study analyzing several cellular markers in the blood of patients with early AD and controls. Neither percentages of monocytes, lymphocytes or granulocytes nor counts of CD4
þ cells did significantly differ between early AD patients (n = 12) and control persons (n = 10). However, CD45R0 low / CD34 þ cell counts were significantly decreased in early AD (T = À2.82; P = 0.017). We assessed the same patients/control persons again enlarging the groups to n = 23 (early AD) and n = 25 (controls). The number of circulating CD45R0 low /CD34 þ stem cells was again significantly decreased as compared with controls (T = À2.68; P = 0.01; Figure 1 ), confirming the data from the first cohorts. Also the new 11 patients and 15 controls in the enlarged sample differed significantly (T = À2.77; P = 0.01).
Intriguingly, only within the AD group CD45R0 low / CD34 þ stem cell counts were highly correlated with age (n = 23; r = À0.661; P = 0.001; Figure 2a) . Furthermore, within the AD group CD45R0 low /CD34 þ cell counts were significantly correlated with CSF Ab1-42 (n = 23; r = À0.467; P = 0.025) and even closer with the Ab ratio 42/40 (n = 15; r = À0.688; P = 0.005; Figure  2b ). The correlations between CD45R0 low /CD34 þ counts and total tau or phospho-tau protein were not significant.
Discussion
This study shows for the first time that counts of circulating HSC are decreased and significantly correlated with age in early AD. As stem cell dysfunction/decrease with increasing age was found also in other stem cell lineages, decreased HSC counts may reflect an accelerated aging process and a premature exhaustion of the stem cell pool in AD. þ stem cell frequency in early AD patients (K) and controls (J). EDTA-anticoagulated whole-blood samples were labeled with anti-CD45R0-FITC and anti-CD34-PE simultaneously, fixed and analyzed with an EPICSXL flow cytometer. The counts refer to a wholeblood volume of 60 ml. The mean is indicated with (&), solid lines within the box mark the median, upper/lower boundaries show the 75th/25th percentiles and whiskers indicate the 95th and 5th percentiles, respectively. The data showed a normal distribution; hence, statistical significance was calculated with the t-tests for unpaired samples (AD, n = 23; CON, n = 25; T = À2.68; P = 0.01). þ HSCs were also found to be decreased in coronary artery disease and to correlate with the number of atherosclerotic risk factors. 16 Interestingly, some risk factors such as hypertension, hypercholesterolemia and diabetes are also relevant for AD. 17 However, in this study, these cardiovascular risk factors were evenly distributed among the AD and control group.
The CD34 surface antigen characterizes a heterogenous population of cells including subsets of hematopoietic or endothelial progenitor cells, mature endothelial cells and tissue committed stem cells. 18 Identifying the most affected sub-populations and understanding the mechanism of HSC consumption and trafficking in AD may help to develop novel diagnostic tools and therapeutic approaches to alleviating the course of the disease.
